[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
March 15, 2000

Bisphosphonate Therapy and Vascular Calcification

Author Affiliations
 

Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor

JAMA. 2000;283(11):1424-1425. doi:10.1001/jama.283.11.1421

To the Editor: The 3-year, randomized controlled trial reported by Dr Harris and colleagues1 demonstrated that risedronate increased bone mineral density and decreased fracture incidence in postmenopausal women with established osteoporosis. Although the overall safety profile was similar in the placebo and risedronate groups, serious adverse events were more common in the treatment group.

First Page Preview View Large
First page PDF preview
First page PDF preview
×